 |
|
|
| |
Efficacy and Safety of Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) or Standard of Care (SOC) in People With HIV-1 (PWH) and Virologic Suppression: Week 48 Integrated Analysis From the Phase 3 ISLEND-1 and ISLEND-2 Trials
|
| |
| |
late breaker
IDWeek 2026 October 21-24 Wash DC
|
| |
|
|
|
|
|
